Retina Sustained Ocular Delivery of Bevacizumab Using Densomeres in Rabbits: Effects on Molecular Integrity and Bioactivity

2022 Update

2022 was a busy and productive year at Sustained Nano Systems. We entered the year with
the new SNS Densomere technology having already shown effectiveness in its ability to
release drugs over the long term ( our studies went out one year) and continue to maintain
its biologic activity. This was further proven by testing molecules placed into SNS
Densomeres by our pharmaceutical clients.

SNS has been selected to present its Densomere Terminal Sterilization Technology at the ARVO (The Association for Research in Vision and Ophthalmology) meeting in Denver, May 1, 2022.

The ARVO Annual Meeting is the premiere gathering for eye and vision scientists at all career stages, students, and those in affiliated fields to share the latest research findings and collaborate on innovative solutions. The 2022 Meeting features both in-person and worldwide virtual participation options. Attendees will have opportunities to network with colleagues and industry thought-leaders.

Selected to present at the HC Wainright Ophtomalogy conference

Sustained Nano Systems, LLC appoints Michael P. Goodman as Chief Financial Officer and Jan S. Peterson as Senior Regulatory Affairs Director.

Sustained Nano Systems appoints Morton Coleman, M.D. Director of Medical Oncology Board.